N/A
N=32
Therapeutic Effects of Constraint-Induced Movement Therapy on Young Children With Cerebral Palsy
Cerebral Palsy Spastic Hemiplegic
Bottom Line
View on ClinicalTrials.gov: NCT03858335 ↗Enrolled (actual)
32
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test — 0.83; 0.00; 0.50; -0.05 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Constraint-induced movement therapy (Other)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Samsung Medical Center
- Primary completion
- Sep 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline Pediatric Motor Activity Log (PMAL) Score at Post Test |
0.83; 0.00; 0.50; -0.05 | — |
| PRIMARY Change From Baseline Accelerometers_Vector Magnitude Average Counts(VMA) at Post Test |
44.73; 8.78 | — |
| SECONDARY Change From Baseline Pediatric Evaluation of Disability Inventory (PEDI) at Post Test |
2.25; 1.25; 2.83; 2.83; 2.83; 0.75 | — |
| SECONDARY Change From Baseline Peabody Developmental Motor Scales-2 (PDMS-2) at Post Test |
0.83; -0.83; 0.92; -0.67 | — |
| SECONDARY Change From Baseline Gross Motor Function Measure (GMFM) at Post Test |
3.33; 4.37 | — |
| SECONDARY Change From Baseline Accelerometers_% Moderate to Vigorous Physical Activity(MVPA) at Post Test |
-2.67; 0.51 | — |
| SECONDARY Change From Baseline Accelerometers_Use Ratio at Post Test |
0.01; -0.02 | — |
Summary
This study evaluates the therapeutic effects of constraint-induced movement therapy on infants and children with hemiplegic cerebral palsy. Half of the participants will receive CIMT (constraint-induced movement therapy) and others will not.
Eligibility Criteria
Inclusion Criteria
- spastic hemiplegic cerebral palsy patients
- 7~36 months old
Exclusion Criteria
- cognitive impairment severe enough to make participation impossible
- uncontrolled epilepsy
- visual or hearing impairment
- musculoskeletal disorders
Data sourced from ClinicalTrials.gov (NCT03858335). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.